US Patent

US11090386 — Method for suppressing bitterness of quinoline derivative

Method of Use · Assigned to Eisai R&D Management Co Ltd · Expires 2036-02-23 · 10y remaining

Vulnerability score 70/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects a method for suppressing the bitterness of a quinoline derivative.

USPTO Abstract

The present invention provides a method for suppressing bitterness of a quinoline derivative.

Drugs covered by this patent

lenvatinib-mesylate (LENVATINIB MESYLATE)

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-3519`	—	lenvatinib-mesylate
`U-3519`	—	lenvatinib-mesylate

Patent Metadata

Patent number: US11090386
Jurisdiction: US
Classification: Method of Use
Expires: 2036-02-23
Drug substance claim: No
Drug product claim: No
Assignee: Eisai R&D Management Co Ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.